Bioequivalence protocol reviews will take longer for drugs with more than three years' patent life left -- OGD.
BIOEQUIVALENCE PROTOCOL REVIEWS FOR DRUGS WITH THREE YEARS OF PATENT LIFE or more left before expiry will take longer than those for products with less than three years of patent protection left, Office of Generic Drugs Acting Director Douglas Sporn informed generic drug firms in an Aug. 18 letter.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth